Welcome to our dedicated page for Cal Maine Foods SEC filings (Ticker: CALM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Egg prices swing with every bushel of corn and every headline about cage-free mandates—so a single line in Cal-Maine Foods’ SEC filings can move the market. Whether you track flock-replacement costs or watch how avian-influenza disclosures ripple through margins, this page distills what matters from the company that puts one in every five U.S. shell eggs on grocery shelves.
Stock Titan’s AI parses each document the moment it lands on EDGAR. Instead of wading through hundreds of pages, you get plain-English takeaways that answer the questions people actually search for—“Cal-Maine Foods SEC filings explained simply” or “understanding Cal-Maine Foods SEC documents with AI.” Real-time alerts surface Cal-Maine Foods Form 4 insider transactions so you see buying or selling by executives before the next pricing cycle hits. Our coverage spans every corner of CALM’s regulatory trail:
- “Cal-Maine Foods annual report 10-K simplified” highlights feed-grain sensitivity and cage-free capital plans.
- “Cal-Maine Foods quarterly earnings report 10-Q filing” pairs AI commentary with trend charts on dozen-egg revenue.
- “Cal-Maine Foods 8-K material events explained” flags outbreaks, plant expansions, or dividend declarations.
- “Cal-Maine Foods proxy statement executive compensation” shows how bonuses hinge on egg-price spreads.
- “Cal-Maine Foods insider trading Form 4 transactions” plus “Cal-Maine Foods Form 4 insider transactions real-time” monitor executive stock moves.
From “Cal-Maine Foods earnings report filing analysis” to “Cal-Maine Foods executive stock transactions Form 4,” investors use these insights to model cash-flow volatility, benchmark feed costs, and gauge bio-security spending—all without leaving a single page.
Lemonade, Inc. (LMND) – Form 4 insider filing
CFO Timothy E. Bixby exercised 7,000 fully-vested employee stock options at an exercise price of $23.69, then sold the same 7,000 shares under a Rule 10b5-1 plan. The sales occurred on 18 Jul 2025 (6,000 sh. at $42.50) and 21 Jul 2025 (1,000 sh. at $42.70), generating gross proceeds of roughly $0.30 million versus an aggregate exercise cost of about $0.17 million.
After the transactions Mr. Bixby’s direct holding remains 263,393 common shares, unchanged from the level prior to the option exercises. He also retains 30,000 shares held indirectly through the Timothy E. Bixby Family Trust and 277,300 unexercised options expiring 25 Sep 2029.
The activity represents <0.02 % of LMND’s 67 million outstanding shares and appears routine portfolio diversification rather than a signal about business fundamentals. No other insiders transacted and no company cash was involved.
Millennium Management LLC and affiliates filed a Schedule 13G disclosing a passive stake in AngioDynamics, Inc. (ANGO). As of 16 Jul 2025 the group beneficially owns between 2.12 M and 2.15 M common shares, equal to ~5.2-5.3 % of the outstanding stock. All voting and dispositive power is reported as shared; no sole authority exists.
The filing covers four reporting persons – Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and founder Israel A. Englander. Each entity is organized in Delaware (Englander is a U.S. citizen) and the shares are held through investment vehicles controlled by Millennium. The group certifies the position was acquired solely for investment purposes and not to influence control of the issuer.
Crossing the 5 % ownership threshold on 07/16/25 triggered the disclosure; a joint filing agreement dated 21 Jul 2025 is included. No purchase prices or additional transaction details are provided.